Corporate News - Archive

Beauty segment: profitability again significantly increased

  • Revenue: +5.7% to EUR 27.1 million (Q1 2025: EUR 25.6 million)
  • EBIT: +37.6% to EUR 9.2 million (Q1 2025: EUR 6.7 million)
  • EBIT margin: 33.9% (Q1 2025: 26.0%)

Group figures: shaped by the sale of HAEMATO Pharm GmbH

  • Group revenue: EUR 46.8 million (Q1 2025: EUR 92.7 million)
  • EBIT: EUR 5.0 million (Q1 2025: EUR 8.8 million)

| Investor News

M1 Kliniken AG (ISIN DE000A0STSQ8) has cancelled the treasury shares acquired under its share buyback programme and reduced its share capital accordingly.

On 25 March 2026, the Management Board resolved, with the approval of the Supervisory Board granted on 26 March 2026 and on the basis of the authorisation by the Annual General Meeting of 17 July 2024, to reduce the Company's share capital by EUR 1,088,289 from EUR 19,643,403 to EUR 18,555,114. The capital reduction became effective upon registration in the commercial register of the Local Court of Charlottenburg (HRB 107637 B) on 26 May 2026.

| Investor News

Group key figures at a glance

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)

| Ad-hoc news

At today's balance sheet meeting, the Supervisory Board of M1 Kliniken AG (ISIN: DE000A0STSQ8) approved the annual financial statements and the consolidated financial statements of the Company for the 2025 financial year, as submitted by the Management Board, in accordance with §§ 171, 172 AktG. The annual financial statements are thereby adopted pursuant to § 172 AktG.

The Supervisory Board and the Management Board today resolved to propose to the Annual General Meeting a dividend of EUR 1.20 per dividend-bearing share.

The 2025 Annual Report of M1 Kliniken AG is expected to be published on 20 May 2026.

| Investor News

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)

| Investor News

M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.

| Investor News

  • Group revenue: +6.7% to EUR 274.3 million (YTD Q3 2024: EUR 257.2 million)
  • EBITDA: +9% to EUR 28.2 million (YTD Q3 2024: EUR 25.9 million)
  • EBIT: +11% to EUR 24.5 million (YTD Q3 2024: EUR 22.1 million)
  • EBIT margin: 8.9% (YTD Q3 2024: 8.6%)
  • EBT: +10% to EUR 24.4 million (YTD Q3 2024: EUR 22.2 million)
  • Earnings per share: EUR 0.86 (YTD Q3 2024: EUR 0.77)

| Ad-hoc news

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.

| Investor News

  • Group revenue: +9.4% to EUR 183.5 million (H1 2024: EUR 167.7 million)
  • EBITDA: +21% to EUR 20.5 million (H1 2024: EUR 17.0 million)
  • EBIT: +24% to EUR 18.0 million (H1 2024: EUR 14.5 million)
  • EBIT margin: 9.8% (H1 2024: 8.6%)
  • EBT: +12% to EUR 16.9 million (H1 2024: EUR 15.0 million)
  • Earnings per share: EUR 0.63 (H1 2024: EUR 0.53)